Poseida Therapeutics Inc. (NASDAQ:PSTX) finished Wednesday with an addition of $0.75 to close at $2.73, an upside of 37.88 percent. An average of 3,875,660 shares of common stock have been traded in the last five days. There was a gain of $1.0800 in the past week, and it reached a new high 21 times over the past 12 months. The last 20 days have seen an average of 1,318,040 shares traded, while the 50-day average volume stands at 1,297,046.
PSTX stock has increased by 40.72% in the last month. The company shares reached their 1-month lowest point of $1.6000 on 08/04/23. With the stock rallying to its 52-week high on 02/08/23, shares of the company touched a low of $1.54 and a high of $8.82 in 52 weeks. It has reached a new high 13 times so far this year and lost -48.49% or -$2.5700 in price. In spite of this, the price is down -69.05% from the 52-week high.
Valuation Metrics
Poseida Therapeutics Inc. (PSTX) stock’s beta is 0.06. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.69, the price-to-book (PB) ratio at 1.49.
Financial Health
The quick ratio of Poseida Therapeutics Inc. for the recent quarter was 5.40, and the current ratio was 5.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.37 and a total debt to equity ratio of 0.37 for the recent quarter. Poseida Therapeutics Inc.’s EBITDA margin is -82.44%, while its operating margin for the same period stands at -30.50%. Its gross profit as reported stood at $190.44 million compared to revenue of $130.49 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Poseida Therapeutics Inc.’s return on assets was -14.30%.
Earnings Surprise
For the recent quarter, Poseida Therapeutics Inc. had $164.7 million in cash and short-term investments compared to $58.4 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$27.46 million in the quarter, while revenues of -$38.85 million were shrunk -111.43%. Shareholders own equity worth $86.78 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Poseida Therapeutics Inc. (PSTX) price momentum. RSI 9-day as of the close on 09 August was 82.76%, suggesting the stock is Overbought, with historical volatility in this time frame at 174.19%.
As of today, PSTX’s price is $1.9900 +65.45% or $1.0800 from its 5-day moving average. PSTX is currently trading +40.00% higher than its 20-day SMA and -34.84% lower than its 100-day SMA. However, the stock’s current price level is +14.71% above the SMA50 and -27.97% below the SMA200.
The stochastic %K and %D were 56.14% and 31.95%, respectively, and the average true range (ATR) was 0.3000. With the 14-day stochastic at 98.69% and the average true range at 0.2600, the RSI (14) stands at 73.07%. The stock has reached 0.3700 on the 9-day MACD Oscillator while the 14-day reading was at 0.4100.
Analyst Ratings
H.C. Wainwright launched coverage on Poseida Therapeutics Inc. (NASDAQ: PSTX) in its analyst report released on January 04, 2023. The firm assigned the stock a Buy rating. The consensus rating for Poseida Therapeutics Inc. (PSTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PSTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is PSTX’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $15.00, with a median target of $12.00. Taking a look at these predictions, the average price target given by analysts for Poseida Therapeutics Inc. (PSTX) stock is $11.80.
